Key Points
- Director George Kemble sold 20,206 Sagimet shares at an average price of $9.95, generating approximately $201,050 and reducing his direct ownership by 24.5% to 62,161 shares.
- Sagimet reported a quarterly loss of $0.26 per share, slightly missing analysts’ $0.25 estimate. The stock opened at $9.39, near its 52-week high of $10.06, with a market capitalization of approximately $306 million.
- Analyst sentiment remains broadly positive, with seven Buy ratings, two Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $26.33; Canaccord recently raised its target to $56.
Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) Director George Kemble sold 20,206 shares of Sagimet Biosciences stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $9.95, for a total value of $201,049.70. Following the sale, the director directly owned 62,161 shares of the company's stock, valued at approximately $618,501.95. The trade was a 24.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
George Kemble also recently made the following trade(s):
- On Monday, July 20th, George Kemble sold 18,844 shares of Sagimet Biosciences stock. The shares were sold at an average price of $7.46, for a total value of $140,576.24.
Sagimet Biosciences Stock Performance
SGMT opened at $9.39 on Thursday. Sagimet Biosciences Inc. has a fifty-two week low of $4.50 and a fifty-two week high of $10.06. The company has a market capitalization of $305.93 million, a P/E ratio of -7.34 and a beta of 3.37. The stock has a fifty day moving average of $7.39 and a 200-day moving average of $6.52.
Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.01). On average, equities research analysts predict that Sagimet Biosciences Inc. will post -1.15 earnings per share for the current fiscal year.
Key Headlines Impacting Sagimet Biosciences
Here are the key news stories impacting Sagimet Biosciences this week:
- Positive Sentiment: Canaccord raises price target: Canaccord Genuity lifted its target for Sagimet from $49 to $56 and maintained a “buy” rating, implying substantial potential upside from recent trading levels. The upgrade reflects a bullish view of the company’s development prospects. Benzinga analyst price target report
- Positive Sentiment: Progress on denifanstat: Wedbush Securities said Sagimet is making “good progress” toward bringing denifanstat to U.S. patients. Positive commentary on the company’s lead drug candidate could support sentiment because future valuation depends heavily on clinical and regulatory execution. Sagimet making progress on denifanstat
- Neutral Sentiment: Short-interest data appears unreliable: Reported short interest was zero shares, unchanged from the prior period, with a zero days-to-cover ratio. Because the figures include an undefined percentage change and may reflect incomplete reporting, they provide little meaningful insight into trading pressure.
- Negative Sentiment: Quarterly loss slightly exceeded expectations: Sagimet reported a second-quarter 2026 loss of $0.26 per share, compared with analysts’ expectation of a $0.25 loss. The modest earnings miss reinforces that the company remains loss-making while it advances its pipeline. Sagimet second-quarter 2026 results
- Negative Sentiment: Director reduced holdings: Director George Kemble sold 20,206 shares for approximately $201,050, reducing his direct ownership by 24.5%. While insider sales can be routine, the transaction may weigh on sentiment because it signals reduced personal exposure by a company director.
Hedge Funds Weigh In On Sagimet Biosciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Sagimet Biosciences by 4.3% in the third quarter. Vanguard Group Inc. now owns 1,203,231 shares of the company's stock valued at $8,254,000 after buying an additional 49,375 shares in the last quarter. Affinity Asset Advisors LLC increased its holdings in shares of Sagimet Biosciences by 228.1% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,148,245 shares of the company's stock worth $6,798,000 after buying an additional 798,245 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Sagimet Biosciences during the fourth quarter worth $4,620,000. Millennium Management LLC lifted its stake in shares of Sagimet Biosciences by 6,484.7% in the 3rd quarter. Millennium Management LLC now owns 776,377 shares of the company's stock valued at $5,326,000 after acquiring an additional 788,537 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Sagimet Biosciences by 82.6% in the 1st quarter. Renaissance Technologies LLC now owns 625,469 shares of the company's stock valued at $3,268,000 after acquiring an additional 282,969 shares during the last quarter. Institutional investors own 87.86% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Sagimet Biosciences in a research report on Friday, July 17th. Guggenheim cut their price target on Sagimet Biosciences from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, April 29th. Canaccord Genuity Group lifted their price objective on Sagimet Biosciences from $49.00 to $56.00 and gave the company a "buy" rating in a report on Wednesday. Oppenheimer reaffirmed an "outperform" rating on shares of Sagimet Biosciences in a report on Friday, May 1st. Finally, Citizens Jmp cut their target price on Sagimet Biosciences from $35.00 to $12.00 and set a "market outperform" rating for the company in a research report on Tuesday, May 19th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Sagimet Biosciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $26.33.
Check Out Our Latest Report on Sagimet Biosciences
About Sagimet Biosciences
(
Get Free Report)
Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company's lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101's potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.
In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
